CERC...Found that as well. Also did a bit more digging. This is a second Ph II trial. First one at lower dose failed, so they're trying again with a higher dose. Safety profile is good.
Certainly risk here but may run a bit as there is some chatter this compound could be better in that it more directly targets MDD.